Profile

Timothy S. Pardee, M.D., Ph.D.Wake Forest Baptist Health

Doctor Rating

4.8 out of 5

84 Ratings
13 Comments
 

Timothy S. Pardee, M.D., Ph.D.

Associate Professor,

Assistant Professor,

Clinical Interests

Acute Leukemias, Acute and Chronic Leukemia, Chronic Leukemias, Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Related Links

Education & Training

  • Ph.D., University of Buffalo - SUNY, 1999
  • M.D., University of Buffalo - SUNY, 2003
  • Residency, Internal Medicine, Massachusetts Gen Hosp, 2005
  • Fellowship, Hematology And Oncology, Stony Brook School of Medicine, 2009

Board Certifications

  • American Board of Internal Medicine, Internal Medicine

NPI Number

  • 1740386010
Timothy S. Pardee, M.D., Ph.D.

Doctor Rating

4.8 out of 5

84 Ratings
13 Comments
 

Timothy S. Pardee, M.D., Ph.D.

Associate Professor, Hematology & Oncology
Comprehensive Cancer Center
Assistant Professor, Cancer Biology

Research Interests

cancer/oncogenesis, drugs/therapeutic agents pharm

Contact Information

Academic: 336-745-0424 | Department: 336-716-4464

Related Links

Recent Publications

Tawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J, Powell BL, Klepin HD. Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). J Geriatr Oncol. 2016;7(1):24-31.

Alexander P, Kucera G, Pardee TS. Improving nucleoside analogs via lipid conjugation: is fatter any better?. Crit Rev Oncol Hematol. 2016;100():46-56.

Gmeiner WH, Jennings-Gee J, Stuart CH, Pardee TS. Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway. Leuk Res. 2015;39(2):229-235.

Pang CS, Pettenati MJ, Pardee TS. Clinicopathological analysis of near-tetraploidy/tetraploidy acute myeloid leukaemia. J Clin Pathol. 2015;68(3):236-240.

Ahmed T, Holwerda S, Klepin HD, Isom S, Ellis LR, Lyerly S, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee TS. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly. Leuk Res. 2015;39(9):945-949.

Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Howard DS, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. Activity of the mitochondrial metabolism inhibitor cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone in high risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. J Clin Oncol. 2015;33(15 Suppl):7015.

Pardee T, Pladna K, Isom S, Ellis LR, Berenzon D, Howard D, Manuel M, Dralle S, Hurd DD, Lyerly S, Powell BL. The mitochondrial metabolism inhibitor Cpi-613 in combination with high dose Ara-C (HDAC) and mitoxantrone is highly active in poor risk relapsed or refractory acute myeloid leukemia (AML) [abstract]. Blood. 2015;126(23):2556.

Klepin HD, Tooze J, Pardee T, Ellis LR, Berenzon D, Howard D, Demark-Wahnefried W, Mihalko S, Rejeski WJ, Powell BL, Kritchevsky S. Feasibility of a symptom-adapted physical activity intervention during induction chemotherapy for older adults with acute myeloid leukemia (AML) [abstract]. Blood. 2015;126(23):2102.

Tawfik B, Sliesoraitis S, Lyerly S, Klepin HD, Lawrence J, Isom S, Ellis LR, Manuel M, Dralle S, Berenzon D, Powell BL, Pardee T. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol. 2014;93(1):47-55.

Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH. The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. Oncotarget. 2014;5(12):4170-4179.

Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol. 2014;32(24):2541-2552.

Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD. The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014;38(10):1184-1190.

Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014;20(20):5255-5264.

Cook GJ, Caudell DL, Elford HL, Pardee TS. The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One. 2014;9(11):e112619.

Marcucci G, Geyer S, Zhao W, Caroll AJ, Bucci D, Uy GL, Blum W, Pardee T, Wetzler M, Stock W, Kolitz JE, Eisfeld AK, Bloomfield CD, Stone RM, Larson RA,. Adding KIT inhibitor dasatinib (DAS) to chemotherapy overcomes the negative impact of KIT mutation/over-expression in core binding factor (CBF) acute myeloid leukemia (AML): results from CALGB 10801 (alliance) [abstract]. Blood. 2014;124(21):8.

Pardee TS, Stadelman K, Isom S, Ellis LR, Berenzon D, Hurd DD, Harrelson R, Manuel M, Dralle S, Lyerly S [sic] [Lyerly ES], Powell BL. The mitochondrial metabolism inhibitor Cpi-613 is highly active in combination with high dose Ara-C (HiDAC) and mitoxantrone in a phase I study for relapsed or refractory acute myeloid leukemia (AML). Blood. 2014;124(21):3744.

Puthiyaveetil AG, Reilly CM, Pardee TS, Caudell DL. Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome. Leuk Res. 2013;37(1):112-116.

Jennings-Gee J, Pardee TS, Gmeiner WH. Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. Exp Hematol. 2013;41(2):180-188.

Cook GJ, Pardee TS. Animal models of leukemia: any closer to the real thing?. Cancer Metastasis Rev. 2013;32(1-2):63-76.

Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS, Ellis LR, Powell BL. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287-4294.

Manny JS, Pardee T, Pettenati M, Pang CS. Near-tetraploid/tetraploid acute myeloid leukemia: morphologic, cytogenetic, and prognostic features [abstract]. Mod Pathol. 2012;25(Suppl 2):354A.

Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Blood. 2012;119(15):3561-3570.

Pardee TS. Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction. PLoS One. 2012;7(8):e43185.

Cook GJ, Caudell DL, Elford HL, Pardee T. The novel ribonucleotide reductase inhibitor didox is active against AML with limited toxicities [abstract]. Blood. 2012;120(21):Abstr 1513.

Pardee TS, Zuber J, Lowe SW. Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. Exp Hematol. 2011;39(4):473-485.

Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, Levitan D, Pardee TS, Isom S, Powell BL. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc. 2011;59(10):1837-1846.

Cook GJ, Elford HL, Pardee T. Activity of the novel ribonucleotide reductase inhibitor didox on human and murine models of acute leukemia [abstract]. Blood. 2011;118(21):1553-1554.

Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP10 results in high efficacy against AML and low toxicity [abstract]. Blood. 2011;118(21):1109-1110.

Pardee T, DeFord-Watts LM, Peronto E, Levitan DA, Hurd DD, Kridel S. Altered lipid and mitochondrial metabolism are viable targets in acute leukemia [abstract]. Blood. 2011;118(21):1546.

Pardee T. Over expression of MN1 accelerates leukemia onset and confers resistance to chemotherapy by suppression of p53 and Bim [abstract]. Blood. 2011;118(21):1070.

Chiou V, Tiegs J, Isom S, Pettenati MJ, Lyerly S, Ellis LR, Pardee T, Dmitriy B, Powell BL, Levitan DA. A single institution analysis of incidence of recurrent chromosomal abnormalities in adult ALL patients according to race, gender, and age [abstract]. Blood. 2011;118(21):4869.

Klepin HD, Tooze JA, Geiger AM, Kritchevsky S, Williamson J, Ellis LR, Levitan D, Pardee T, Isom S, Powell BL. Geriatric assessment predicts overall survival among older adults receiving induction chemotherapy for acute myelogenous leukemia [abstract]. Blood. 2010;116(21):653-654.

Pardee T, Mascenik T, Bolemon BH, Cook GJ. Over expression of MN1 confers resistance to chemotherapy in vitro and in vivo [abstract]. Blood. 2010;116(21):427.

Pardee T, Gomes E, Jennings-Gee J, Caudell DL, Gmeiner W. The novel fluoropyrimidine FdUMP[10] is highly active against acute myeloid leukemia [abstract]. Blood. 2010;116(21):1353.

Pardee T, Zuber J, Lowe S. The FLT3 ITD accelerates an already established myeloid leukemia and alters chemotherapy response in vitro and in vivo in a p53 dependent manner [abstract]. Blood. 2009;114(22):685.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Hematology & Oncology

Clinical Interests

Acute Leukemias, Acute and Chronic Leukemia, Chronic Leukemias, Hematologic Malignancies, Leukemia, Myelodysplastic Syndromes
Timothy S. Pardee, M.D., Ph.D.

Timothy S. Pardee, M.D., Ph.D.

Associate Professor, Hematology & Oncology
Comprehensive Cancer Center
Cancer Biology

Doctor Rating

4.8 out of 5

Timothy S. Pardee, M.D., Ph.D.84 Ratings
13 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.9
CP efforts to include in decisions
4.9
CP explanations of prob/condition
4.8
CP spoke using clear language
4.9
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.9
Patients' confidence in CP
4.9
Time CP spent with patient
4.8
Wait time at clinic
4.0



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

2/17/2016

*Dr. Pardee & assistant, *Lauren Imboden, are both good caregivers. They genuinely seem to care for me.

2/17/2016

*Dr. PA & nurses were all so wonderful. They didn't talk in language we couldn't understand - very informative.

1/28/2016

All good.

1/10/2016

All good

1/7/2016

*Dr. Pardee is one of the best physicians I have ever been involved with.

10/7/2015

Good.

9/16/2015

My provider may just find the fixens to change my health issue.

9/2/2015

I am fortunate to have chosen this facility for my treatment. I feel that these people saved my life with the help of GOD!!

8/19/2015

Great! Wonderful staff!

8/11/2015

Very good & personable.

7/6/2015

*Dr. Pardee very knowledgeable and well respected.

6/22/2015

Outstanding care received by provider.

5/12/2015

Our experience with all the hospital staff was very good.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2015-2016Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.